June 20, 2013
2 min read

Combination immunotherapy controls inflammation in birdshot retinochoroidopathy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Cyclosporine A and mycophenolate mofetil controlled inflammation in the treatment of birdshot retinochoroidopathy, according to a study.

The retrospective study included 98 eyes of 49 patients with birdshot retinochoroidopathy.

Initial dosages were 3 mg per kg of weight for cyclosporine A and 1 g twice daily for mycophenolate mofetil. Dosages were changed in patients who showed no improvement or experienced adverse events. The drugs were discontinued for at least 2 weeks in patients with side effects or drug toxicity until symptoms or laboratory abnormalities resolved.

There were statistically significant reductions in vitreous inflammation scores in right eyes (P < .001) and left eyes (P = .001) at 1 year. Inflammation was controlled successfully in 31 of 46 patients (67.4%) at 1 year.

Angiographic leakage of retinal vessels decreased significantly (P = .0039). There was no significant decrease in cystoid macular edema.

Changes in logMAR best corrected visual acuity were insignificant at 1 year.